Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma Trading AD's revenue for the
three
months ended in Mar. 2026 was €303 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €1,178 Mil.
Sopharma Trading AD's Revenue per Share for the
three
months ended in Mar. 2026 was €8.87.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €34.40.
Good Sign:
Sopharma Trading AD has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Sopharma Trading AD was 13.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 16.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 14.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Sopharma Trading AD's highest 3-Year average Revenue per Share Growth Rate was 16.10% per year. The lowest was 6.10% per year. And the median was 13.05% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Sopharma Trading AD Revenue Related Terms
Sopharma Trading AD Revenue Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma Trading AD's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD Revenue vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Revenue distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,178 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD (FRA:6YH) has a Revenue of €1,178 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Sopharma Trading AD and its competitors.
Is Sopharma Trading AD's Revenue too high?
Sopharma Trading AD's current Revenue is €1,178 Mil. Overall, Sopharma Trading AD has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Revenue compare to MCK and COR?
Sopharma Trading AD's Revenue of €1,178 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Distribution company?
A good Revenue depends on the Medical Distribution industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Sopharma Trading AD and its competitors. Sopharma Trading AD's current Revenue is €1,178 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Sopharma Trading AD (FRA:6YH) has a current Revenue of €1,178 Mil. The stock's GF Value™ is €7.45, compared to a current price of €2.88 — trading 61.3% below its estimated fair value. The current Revenue is €1,178 Mil. Sopharma Trading AD's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Sopharma Trading AD (FRA:6YH), the current Revenue is €1,178 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (FRA:6YH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.88 is trading 61.3% below its estimated GF Value™ of €7.45.
Key valuation signals for FRA:6YH:
Revenue: €1,178 Mil
GF Value™: €7.45 vs. price of €2.88 (61.3% below fair value)
No single metric tells the full story. See the FRA:6YH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
84GF Score
Get the complete analysis for FRA:6YH
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YH has been successfully added to your 
